breast highlights asco

1. ASCO Highlights of the Day<br />Breast Cancer Local/Regional/Adjuvant
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

2. Highlights
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

3. LUMINA: A Prospective Trial Omitting Radiotherapy following Breast Conserving Surgery in T1N0 Luminal A Breast Cancer
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

4. Slide 4
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

5. Central Ki67 Testing
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

6. Slide 6
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

7. Slide 7
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

8. Conclusions
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

9. Is 5 years enough follow up?
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

10. Are low ki67 patients low-risk or delayed risk?
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

11. “Low risk” by Multi-gene Assay Associated with Low LRR after Lumpectomy and WBI
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

12. Can a Multi Gene Assay Define Breast Conservation Without RT?<br />Multiple Ongoing Clinical Trials
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

13. NRG BR007 Schema
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

14. Slide 14
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

15. Post-lumpectomy DCIS +/- Tamoxifen, <br />NSABP B-24
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

16. 7-gene DCIS Biosignature Score
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

17. SweDCIS: Interaction analysis between DS and radiation therapy
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

18. Study Population
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

19. Patient distribution by 7-gene Biosignature Risk groups (3)
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

20. Adjuvant Radiation Therapy benefit within Biosignature Risk groups
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

21. Adjuvant Endocrine Therapy effect within Biosignature Risk groups
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

22. Conclusions
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

23. Final results from a phase III randomized clinical trial<br />of adjuvant endocrine therapy ± chemotherapy<br />in women ≥ 70 years old with ER+ HER2- breast cancer and a high
genomic grade index:<br />the Unicancer ASTER 70s trial
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

24. Genomic Tools for BC and Older Patients
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

25. ASTER 70s Study Design<br />Adjuvant systemic treatment for ER+ HER2- BC in women over 70 according to GGI<br />Hypothesis: 4-year OS with CT ET > 4-year OS with ET only if
high GGI
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

26. Statistical considerations
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

27. Treatment Realization in Randomized Patients
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

28. OS: ET ── vs CT ET ── (ITT)
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

29. OS: ET ── vs CT ET ── (per protocol)
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

30. Conclusions
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

31. Event-free Survival by Residual Cancer Burden After Neoadjuvant Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy for Early-Stage TNBC: Exploratory Analysis From
KEYNOTE-522
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

32. KEYNOTE-522 Study Design (NCT03036488)
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

33. EFS Analysis by RCB Category
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

34. EFS in RCB-2
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

35. Summary and Conclusions
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

36. Thank You!
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.